Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Non-cash Items (2021 - 2024)

Historic Non-cash Items for Gain Therapeutics (GANX) over the last 3 years, with Q4 2024 value amounting to $1.9 million.

  • Gain Therapeutics' Non-cash Items changed N/A to $1.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.9 million, marking a year-over-year change of. This contributed to the annual value of $1.9 million for FY2024, which is N/A changed from last year.
  • Per Gain Therapeutics' latest filing, its Non-cash Items stood at $1.9 million for Q4 2024.
  • In the past 5 years, Gain Therapeutics' Non-cash Items registered a high of $2.6 million during Q2 2022, and its lowest value of $126549.0 during Q3 2021.
  • In the last 3 years, Gain Therapeutics' Non-cash Items had a median value of $682379.0 in 2021 and averaged $971839.0.
  • Data for Gain Therapeutics' Non-cash Items shows a peak YoY increase of 18912.2% (in 2022) and a maximum YoY decrease of 7020.47% (in 2022) over the last 5 years.
  • Over the past 3 years, Gain Therapeutics' Non-cash Items (Quarter) stood at $163237.0 in 2021, then soared by 124.14% to $365881.0 in 2022, then surged by 421.24% to $1.9 million in 2024.
  • Its Non-cash Items stands at $1.9 million for Q4 2024, versus $365881.0 for Q3 2022 and $2.6 million for Q2 2022.